Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Gossamer Bio (NASDAQ:GOSS) has entered into an option agreement to acquire Respira Therapeutics, a Samsara BioCapital portfolio company. The deal centers around RT234, a first-in-class inhaled vardenafil powder being developed as an as-needed (PRN) treatment for pulmonary hypertension (PH).
As part of the agreement, Gossamer will issue 2.5 million shares upfront and an additional 1.5 million shares upon exercising the acquisition option. The deal includes success-based milestone payments and royalties on potential RT234 sales. During the two-year option period, Gossamer will fund CMC development activities for RT234.
Gossamer Bio (NASDAQ:GOSS) ha stipulato un accordo di opzione per acquisire Respira Therapeutics, una società del portafoglio Samsara BioCapital. L'accordo riguarda RT234, una polvere inalabile di vardenafil di prima classe sviluppata come trattamento PRN per l'ipertensione polmonare (PH).
Come parte dell'accordo, Gossamer emetterà 2,5 milioni di azioni upfront e ulteriori 1,5 milioni di azioni al momento dell'esercizio dell'opzione di acquisizione. L'operazione prevede pagamenti di milestone basati sul successo e royalty su potenziali vendite di RT234. Nel corso del periodo di opzione di due anni, Gossamer finanzierà le attività di sviluppo CMC per RT234.
Gossamer Bio (NASDAQ:GOSS) ha suscrito un acuerdo de opción para adquirir Respira Therapeutics, una empresa de la cartera Samsara BioCapital. El acuerdo se centra en RT234, un polvo inhalado de vardenafilo de primera clase que se está desarrollando como tratamiento PRN para la hipertensión pulmonar (PH).
Como parte del acuerdo, Gossamer emitirá 2,5 millones de acciones por adelantado y 1,5 millones de acciones adicionales al ejercitar la opción de adquisición. El trato incluye pagos por hitos de éxito y regalías sobre las posibles ventas de RT234. Durante el período de opción de dos años, Gossamer financiará las actividades de desarrollo CMC para RT234.
Gossamer Bio (NASDAQ:GOSS)는 Respira Therapeutics, Samsara BioCapital 포트폴리오 기업을 인수하기 위한 옵션 계약을 체결했습니다. 이 거래는 PRN(필요 시) 요법으로 개발 중인 1급 inhaled vardenafil 파우더인 RT234를 중심으로 이루어집니다.
계약의 일부로 Gossamer는 선지급으로 250만 주를 발행하고 인수 옵션을 행사할 때 추가로 150만 주를 발행합니다. 이 거래에는 성공 기반 마일스톤 지불 및 RT234 판매에 대한 로열티가 포함되어 있습니다. 2년간의 옵션 기간 동안 Gossamer는 RT234의 CMC 개발 활동에 자금을 지원합니다.
Gossamer Bio (NASDAQ:GOSS) a conclu un accord d'option pour acquérir Respira Therapeutics, une société du portefeuille Samsara BioCapital. L'accord se concentre sur RT234, une poudre inhalable de vardénafil de première classe développée comme traitement PRN pour l'hypertension pulmonaire (HP).
Dans le cadre de l'accord, Gossamer émettra 2,5 millions d'actions immédiatement et 1,5 millions d'actions supplémentaires lors de l'exercice de l'option d'acquisition. L'accord prévoit des paiements d'étapes basés sur le succès et des redevances sur les ventes potentielles de RT234. Pendant la période d'option de deux ans, Gossamer financera les activités de développement CMC de RT234.
Gossamer Bio (NASDAQ:GOSS) hat eine Optionsvereinbarung zum Erwerb von Respira Therapeutics unterzeichnet, einer Portfoliounternehmen von Samsara BioCapital. Die Vereinbarung dreht sich um RT234, ein erstklassiges inhalierbares Vardenafil-Pulver, das als bedarfsorientierte (PRN) Behandlung für Lungenerkrankungen (PH) entwickelt wird.
Im Rahmen der Vereinbarung wird Gossamer 2,5 Millionen Aktien upfront ausgeben und bei Ausübung der Erwerbsoption zusätzliche 1,5 Millionen Aktien emittieren. Die Transaktion sieht erfolgsbasierte Meilensteinzahlungen und Royalties auf potenzielle RT234-Verkäufe vor. Während des zweijährigen Optionszeitraums wird Gossamer die CMC-Entwicklungsaktivitäten für RT234 finanzieren.
Gossamer Bio (NASDAQ:GOSS) أبرمت اتفاقية خيار للاستحواذ على Respira Therapeutics، وهي شركة ضمن محفظة Samsara BioCapital. يتركز الاتفاق حول RT234، وهو مسحوق فياردينافيل مستنشَق من الفئة الأولى يُطوَّر كعلاج حسب الحاجة (PRN) لارتفاع ضغط الدم الرئوي (PH).
كجزء من الاتفاق، ستصدر Gossamer 2.5 مليون سهم مقدمًا وهناك 1.5 مليون سهم إضافية عند ممارسة خيار الاستحواذ. يشمل الاتفاق دفعات milestones مرتبطة بالنجاح وحقوق ملكية على المبيعات المحتملة لـ RT234. وخلال فترة الخيار التي تمتد لمدة سنتين، ستموّل Gossamer أنشطة تطوير CMC لـ RT234.
Gossamer Bio (NASDAQ:GOSS) 已签署一项购买权协议，拟收购Respira Therapeutics，该公司是Samsara BioCapital的投资组合公司。交易重点在于RT234，这是一种首创的吸入型伐地那非粉末，正作为按需（PRN）治疗肺动脉高压（PH）进行开发。
根据协议，Gossamer将一次性发行250万股，在行使收购权时再发行150万股。该交易包括基于成功的里程碑支付和对潜在RT234销售的特许权使用费。在为期两年的期权期内，Gossamer将资助RT234的CMC开发活动。
- Development of first-in-class as-needed (PRN) therapy for pulmonary hypertension where no PRN options currently exist
- Gossamer to fund development activities during the option period
- Deal includes milestone payments and royalties on potential sales
- Leverages Gossamer's established late-stage PH product development platform
- Two-year option period creates uncertainty about final acquisition completion
- Share-based transaction structure may lead to dilution for existing Gossamer shareholders
Insights
Gossamer's option deal to acquire Respira adds potential first PRN PH treatment to pipeline with structured, milestone-based financial terms.
Gossamer Bio's option agreement to acquire Respira Therapeutics represents a strategically structured deal that expands their pulmonary hypertension (PH) pipeline with minimal upfront capital commitment. The transaction centers around RT234, a vardenafil inhalation powder being developed as the first-ever as-needed (PRN) treatment for PH conditions, addressing an unmet need in a market where patients continue struggling with symptoms despite existing therapies.
The financial structure is notably favorable for Gossamer's near-term cash position. The initial consideration consists of
The two-year option period gives Gossamer valuable time to evaluate RT234's potential while funding only specific CMC (Chemistry, Manufacturing, and Controls) activities - essentially a lower-risk extended due diligence period. This structure allows Gossamer to assess development risks before fully committing to the acquisition, while positioning the asset for accelerated development if acquired.
For Gossamer, which has established expertise in late-stage PH product development, this transaction logically extends their therapeutic focus while potentially adding a unique, first-in-class asset addressing daily function limitations in PH patients. The milestone-based payment structure aligns Respira's compensation with actual development success, reducing Gossamer's risk exposure in this transaction.
- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD -
Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed (PRN) therapy for use in pulmonary hypertension (PH). RT234 is designed to rapidly improve PH patient function and symptoms, including for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). There are no approved PRN therapies for PAH or PH-ILD, and despite existing treatment options, the majority of PH patients continue to struggle with debilitating symptoms that disrupt daily life and limit their independence.
"We look forward to working closely with our colleagues at Gossamer, who share our commitment to people living with PH, to expeditiously develop RT234 and making this unique therapy broadly available to patients," stated John Kollins, Respira's Chief Executive Officer.
"We are excited to pair Respira's technology and expertise with Gossamer's established late-stage PH product development platform," said Michael Dybbs, member of the Respira Board of Directors and partner at Samsara BioCapital. "We are confident that this transaction favorably positions RT234 to advance into late-stage clinical development."
Pursuant to the option agreement, Gossamer is issuing 2.5 million shares of common stock in connection with the signing. Additionally, upon exercise of its acquisition option, Gossamer will issue an additional 1.5 million shares of common stock. In addition, the acquisition agreement provides for certain success-based clinical, regulatory, and commercial milestone payments and a royalty on potential net sales of RT234. During the option period, which is anticipated to continue for up to approximately two years, Gossamer will fund and Respira will undertake certain pre‑agreed development activities focused on CMC work necessary to position RT234 for successful subsequent clinical development.
Respira is being advised by Sidley Austin LLP,
About Respira Therapeutics and RT234
Respira Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary hypertension patients can self-administer as-needed (PRN) to provide rapid, on-demand relief of exertional symptoms, such as breathlessness and reduced ability to perform basic daily activities, on top of chronic background therapies. These symptoms are widely prevalent among PH patients and often highly debilitating and disruptive to patients' daily lives.
RT234 incorporates novel and proprietary dry-powder formulation and inhaler technologies, including Respira's Axial Oscillating Sphere Dry Powder Inhaler (AOS™-DPI), which maximize drug delivery to the deep lung. Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor approved in an oral dosage form for a non-PH indication. Although the PDE5 inhibitors sildenafil and tadalafil are FDA-approved in oral dosage forms for chronic treatment of PAH, on-demand administration of PDE5 inhibitors by inhalation in PH represents a novel treatment approach. Unlike existing PH treatments, RT234 is designed to provide rapid, on-demand relief of exertional symptoms and to be used on top of background therapies.
In two completed open‑label Phase 2 studies in which a total of 56 PAH patients were treated with RT234, RT234 demonstrated rapid and clinically meaningful improvements in both hemodynamic and functional measures. Hemodynamic benefits included reductions in pulmonary vascular resistance and favorable changes in mean pulmonary arterial pressure and cardiac output. Acute functional improvements were also observed, including reduced breathlessness and increased exercise capacity during cardiopulmonary exercise testing. To date, RT234 has demonstrated a favorable safety and tolerability profile.
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
About Samsara BioCapital
Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs. Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by Srinivas Akkaraju, who has over twenty-seven years of industry experience and has an MD and a PhD in Immunology from Stanford University.
Contact:
Respira Therapeutics, Inc.
John Kollins
Chief Executive Officer
ir@respiratherapeutics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/respira-therapeutics-enters-into-agreement-with-gossamer-bio-gossamer-granting-gossamer-option-to-acquire-respira-from-samsara-biocapital-302567055.html
SOURCE Respira Therapeutics, Inc.
FAQ
What is the acquisition deal between Gossamer Bio and Respira Therapeutics?
What is RT234 and how is it different from existing treatments?
How long is the option period for Gossamer Bio's potential acquisition of Respira?
What are the financial terms of the Gossamer Bio (GOSS) and Respira deal?
What is the potential market impact of RT234 for pulmonary hypertension patients?
